M/s. Planet Pharma Pharmaceutical Import Profile — France (DGFT 2022–2026)

Name: M/s. Planet Pharma Pharmaceutical Import Records from India — 4 Products, $2.8M FOB USD (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

M/s. Planet Pharma — Pharmaceutical Importer Profile (2026) | 4 Products, $2.8M Trade | TransData Nexus

Who Are the Verified Indian Suppliers to M/s. Planet Pharma?

Customs-verified supplier relationships from Indian DGFT records

Supplier	Value	Shipments	Share
Sun Pharmaceutical Industries Limited	$818.7K	48	42.1%
Aurochem Pharmaceuticals India Privatelimited	$673.7K	52	34.7%
Aurochem Pharmaceuticals India Private Limited	$430.0K	31	22.1%
Agog Pharma Limited	$11.4K	1	0.6%
Franco-indian Pharmaceuticals Private Limited	$6.0K	2	0.3%
Cadila Pharmaceuticals Limited	$2.6K	1	0.1%
Fredun Pharmaceuticals Limited	$0	6	0.0%

M/s. Planet Pharma sources from 7 verified Indian suppliers across 99 distinct formulations. The supply base is diversified across 7 suppliers, reducing single-source dependency risk.

What Formulations Does M/s. Planet Pharma Import?

Formulation	Value	Ships
Bonecare	$213.9K	5
Solfer syrup	$139.7K	6
Zolcer kit	$100.0K	2
Bacqure INJ 500 MG 30ML 1 s fwa Pack 1vial batch	$100.0K	2
Ranferon plus cap 3x10s fwa Pack 03 10batch	$68.1K	3
Feverlet	$59.3K	3
Scarid gel	$51.2K	4
Pharmaceutical products solfer

What Products Does M/s. Planet Pharma Import?

Top Products by Import Value

1Strip$2.0M 2Volini$402.3K 3Chondroitin$279.2K 4Glucosamine$183.9K

M/s. Planet Pharma Therapeutic Categories — 3 Specializations

M/s. Planet Pharma imports across 3 therapeutic categories, with Medical Devices & Diagnostics (69.5%), Nutritional Supplements (16.3%), Brand Names & OTC Products (14.2%) representing the largest segments. The portfolio is concentrated — top 5 products = 100% of total imports.

Import Portfolio — Top 4 by Import Value

#	Product	Category	Value	Ships	Share	Rk
1	Strip	Medical Devices & Diagnostics	$2.0M	111	1.0%	20
2	Volini	Brand Names & OTC Products	$402.3K	22	12.5%

Key Metrics

Total Import Value$2.8M

Products4

Shipments159

Categories3

CountryFrance

#1 Rankings0

Indian Suppliers7

Formulations99

Top Categories

Medical Devices & Diagnostics69.5%

Nutritional Supplements16.3%

Last updated: March 28, 2026

M/s. Planet Pharma — Corporate Profile & Information

Company type, headquarters, distribution network, and industry role

1Company Overview

M/s. Planet Pharma is a pharmaceutical importer based in Le Grand-Quevilly, France. The company specializes in sourcing finished pharmaceutical formulations, including tablets, capsules, syrups, and injections, primarily from India. With a total import value of $2.8 million USD over 159 shipments from 2022 to 2026, Planet Pharma plays a significant role in the French pharmaceutical distribution network. The company's product portfolio encompasses four distinct products across three therapeutic categories, indicating a diversified approach to meeting market demands.

In the French pharmaceutical supply chain, Planet Pharma functions as a key importer, facilitating the entry of various pharmaceutical products into the market. By establishing partnerships with multiple Indian suppliers, the company ensures a steady supply of diverse pharmaceutical formulations, contributing to the availability of essential medications within France.

2Distribution Network

Planet Pharma's distribution network is strategically located in Le Grand-Quevilly, France, serving as a central hub for the import and distribution of pharmaceutical products. While specific details regarding warehouse locations and logistics capabilities are not publicly disclosed, the company's consistent import activity suggests a well-organized supply chain capable of efficiently managing the flow of goods from international suppliers to the French market. The geographic coverage primarily focuses on France, with potential for expansion into neighboring European markets, leveraging France's position as a gateway to the European Union.

Supplier Relationship Intelligence — M/s. Planet Pharma

Sourcing concentration, supply chain resilience, and strategic implications

1Sourcing Concentration Analysis

Planet Pharma's sourcing strategy exhibits a notable concentration, with the top five products accounting for 100% of the total import value. This indicates a high dependency on a limited product range, which could pose risks such as supply chain disruptions or market fluctuations affecting these specific products. The company's reliance on a select group of products suggests a strategic focus on high-demand items, but it also highlights the need for diversification to mitigate potential risks. The shipment data reveals a stable relationship with Indian suppliers, as evidenced by the consistent import activity over the years. However, the lack of diversification in product sourcing may limit Planet Pharma's ability to adapt to changing market demands or regulatory changes affecting specific product categories.

2Supply Chain Resilience

Planet Pharma's supply chain resilience is closely tied to its sourcing strategy. The company's concentration on a limited number of products from a select group of Indian suppliers may expose it to risks associated with supply chain disruptions, such as production delays or regulatory changes in the supplier's country. The absence of publicly available information regarding backup suppliers or alternative sourcing strategies suggests a potential vulnerability in the supply chain. Additionally, the lack of diversification in product formulations imported may limit the company's ability to adapt to shifts in market demand or therapeutic trends. To enhance supply chain resilience, Planet Pharma could consider diversifying its supplier base and product portfolio, thereby reducing dependency on specific suppliers and products.

3Strategic Implications

Planet Pharma's concentrated sourcing pattern positions it as a specialized importer focusing on high-demand pharmaceutical products. This strategy allows the company to establish strong relationships with key suppliers and potentially negotiate favorable terms. However, the lack of product and supplier diversification may limit the company's ability to adapt to changing market conditions or regulatory environments. For Indian exporters, this presents an opportunity to become alternative suppliers by offering a broader range of products or by diversifying their offerings to meet Planet Pharma's needs. By understanding the company's sourcing patterns, Indian exporters can tailor their strategies to align with Planet Pharma's requirements, potentially securing a position within its supply chain.

TransData Nexus Research · Verified DGFT customs dataMar 2026

Importing Pharmaceuticals into France — Regulatory Framework

Regulatory authority, GMP requirements, import licensing for France

1Regulatory Authority & Framework

In France, the primary regulatory authority overseeing pharmaceutical imports is the French National Agency for Medicines and Health Products Safety (ANSM). ANSM is responsible for ensuring the safety, efficacy, and quality of health products, including pharmaceuticals, medical devices, and cosmetics. Key legislation governing pharmaceutical imports includes the Public Health Code, which outlines the requirements for marketing authorization, importation, and distribution of pharmaceutical products. The marketing authorization pathway for Indian generics involves obtaining a Marketing Authorization (MA) from ANSM, which requires submission of comprehensive documentation demonstrating the product's quality, safety, and efficacy. Additionally, compliance with Good Manufacturing Practice (GMP) standards, as recognized by ANSM, is mandatory for all pharmaceutical products imported into France.

2Import Licensing & GMP

Import licensing requirements in France stipulate that all pharmaceutical products must have a valid Marketing Authorization (MA) issued by ANSM. This authorization is contingent upon the product meeting ANSM's standards for quality, safety, and efficacy. Good Manufacturing Practice (GMP) certification is a critical component of the import process. ANSM recognizes GMP certifications from the European Union (EU), the World Health Organization (WHO), and the Pharmaceutical Inspection Co-operation Scheme (PIC/S). Indian exporters seeking to supply pharmaceutical products to France must ensure that their manufacturing facilities are GMP-compliant and that their products have obtained the necessary MA from ANSM. Additionally, wholesale distribution authorization is required for entities involved in the distribution of pharmaceutical products within France, ensuring that all intermediaries in the supply chain adhere to regulatory standards.

3Quality & Labeling

Pharmaceutical products imported into France are subject to stringent quality control measures, including batch testing and stability studies, to ensure their safety and efficacy. Labeling requirements mandate that all information be provided in French, including product name, dosage form, strength, and usage instructions. Serialization mandates are enforced to enhance traceability and prevent counterfeit products from entering the market. These requirements are in line with EU regulations and are enforced by ANSM to maintain the integrity of the pharmaceutical supply chain.

4Recent Regulatory Changes

Between 2024 and 2026, France implemented several regulatory changes affecting pharmaceutical imports, including those from India. These changes encompassed stricter compliance with EU regulations on Good Manufacturing Practice (GMP), enhanced requirements for marketing authorization, and more rigorous batch testing protocols. Additionally, France introduced updated labeling and serialization mandates to align with EU directives aimed at combating counterfeit medicines. These regulatory updates necessitate that Indian pharmaceutical exporters adapt their manufacturing and documentation processes to meet the new standards, ensuring continued access to the French market.

TransData Nexus Research · France regulatory databasesMar 2026

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Analysis Methodology

1.Buyer Matching: M/s. Planet Pharma identified across shipments using consignee name normalization, aggregating 4 name variants.
2.Statistical Normalization: Shipment values are statistically normalized to ensure accurate market share representation.
3.Market Share: Calculated per product as M/s. Planet Pharma's capped value divided by total Indian exports for that product.
4.Shipment Count: Based on 159 individual customs records matching M/s. Planet Pharma.
5.Supplier Verification: M/s. Planet Pharma sources from 7 verified Indian suppliers across 99 formulations, confirmed from customs records.

Government-Sourced Data

Official DGFT customs records

Transparent Methodology

Calculations fully disclosed above

4 Products Tracked

3 therapeutic categories

Expert-Reviewed

By pharmaceutical trade specialists

M/s. Planet Pharma

M/s. Planet Pharma — Import Portfolio & Supplier Network

Who Are the Verified Indian Suppliers to M/s. Planet Pharma?

What Formulations Does M/s. Planet Pharma Import?

What Products Does M/s. Planet Pharma Import?

Top Products by Import Value

M/s. Planet Pharma Therapeutic Categories — 3 Specializations

Import Portfolio — Top 4 by Import Value

Key Metrics

Top Categories

M/s. Planet Pharma — Corporate Profile & Information

1Company Overview

2Distribution Network

Indian Suppliers

Related Trade Data

Need Detailed Data?

3Industry Role

Supplier Relationship Intelligence — M/s. Planet Pharma

1Sourcing Concentration Analysis

2Supply Chain Resilience

3Strategic Implications

Importing Pharmaceuticals into France — Regulatory Framework

1Regulatory Authority & Framework

2Import Licensing & GMP

3Quality & Labeling

4Recent Regulatory Changes

M/s. Planet Pharma — Procurement Pattern Analysis

1Product Strategy

2Sourcing Profile

3Market Positioning

Seller's Guide — How to Become a Supplier to M/s. Planet Pharma

1Opportunity Assessment

2Requirements & Qualifications

3How to Approach

Frequently Asked Questions — M/s. Planet Pharma

What products does M/s. Planet Pharma import from India?

Who supplies pharmaceuticals to M/s. Planet Pharma from India?

What is M/s. Planet Pharma's total pharmaceutical import value?

What therapeutic categories does M/s. Planet Pharma focus on?

Get Full M/s. Planet Pharma Import Intelligence

Official References & Regulatory Resources

Research Methodology & Data Transparency

Suresh Sormare

Primary Data Source

Analysis Methodology

Data Source & Methodology